Kashfia Chowdhury

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Dilan Athauda, Kate Maclagan, Simon S. Skene et al. · The Lancet · 2017 · 851 citations · Full text

Medicine, Neurology, Pharmacology +12

Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms That Affect Motor Function in Patients With Parkinson Disease

Dilan Athauda, Seema Gulyani, Hanuma Kumar Karnati et al. · JAMA Neurology · 2019 · 256 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17

Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · The Lancet · 2025 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Total Ankle Replacement Versus Arthrodesis for End-Stage Ankle Osteoarthritis

Kashfia Chowdhury, Ekaterina Bordea, Iva Hauptmannova et al. · Annals of Internal Medicine · 2022 · 84 citations

Medicine, Orthopaedic Surgery, Orthopedic Surgery +17

Exenatide once weekly over 2 years as a potential disease-modifying treatment for Parkinson’s disease: protocol for a multicentre, randomised, double blind, parallel group, placebo controlled, phase 3 trial: The ‘Exenatide-PD3’ study

Nirosen Vijiaratnam, Christine Girges, Grace Auld et al. · BMJ Open · 2021 · 82 citations · Full text

Medicine, Neurology, Pharmacology +16